Vipul H. Shah, MD, FACP

Bachelor’s Degree – Rutgers University

Medical Degree – UMDNJ/Rutgers Medical School

Internship – New York Presbyterian/Columbia University

Residency – New York Presbyterian/Columbia University

Fellowship – New York Presbyterian/Columbia University

Board Certifications – Gastroenterology, Internal Medicine

12 week randomized double blind, placebo controlled study of the efficacy and tolerability of Alosetron HC lmg BID for the control of bowel urgency in females with nonconstipated JBS in and independent practioner association model. Protocol #S3B40051. 2000
START: Standard Therapeutic Assessment of Rebetron Trial. Indiana University Indiana.
A Comparative Efficacy Study of Esomeprazole and Lansoprazole in patients with Erosive Esophagitis.Protocol #267. 2000
Roche Labs, Inc. Prospective randomize multicenter open label comparative safety study of Pegasys vs Pegasys plus ribavarin in treatment of patients with Hep C “Wings Trial” May 2001
Proctor and Gamble. Asacol 4.8gm/day vs. 2.4gm/day in mild to moderate ulcerative colitis patients experiencing an active flare. March 200I
Abbott Labs. Multi Center randomized double blind, placebo controlled study of Human Anti-TNF Monoclonal antibody Adalimurnab for the induction and maintenance of clinical remission in subjects with Crohn’s disease. April 2003
GlaxoSmithKline. A 12 week randomized double blinded placebo controlled study of PRN BID and fixed dosing regimens of alosetron in female subjects with severe diarrhea-predominant irritable bowel syndrome who have failed conventional therapy. September 2003.

Footer